GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ascelia Pharma AB (OSTO:ACE) » Definitions » ROE %

Ascelia Pharma AB (OSTO:ACE) ROE % : -111.97% (As of Sep. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Ascelia Pharma AB ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Ascelia Pharma AB's annualized net income for the quarter that ended in Sep. 2024 was kr-86.93 Mil. Ascelia Pharma AB's average Total Stockholders Equity over the quarter that ended in Sep. 2024 was kr77.63 Mil. Therefore, Ascelia Pharma AB's annualized ROE % for the quarter that ended in Sep. 2024 was -111.97%.

The historical rank and industry rank for Ascelia Pharma AB's ROE % or its related term are showing as below:

OSTO:ACE' s ROE % Range Over the Past 10 Years
Min: -85.65   Med: -42.42   Max: -19.15
Current: -82.61

During the past 7 years, Ascelia Pharma AB's highest ROE % was -19.15%. The lowest was -85.65%. And the median was -42.42%.

OSTO:ACE's ROE % is ranked worse than
70.19% of 1305 companies
in the Biotechnology industry
Industry Median: -43.68 vs OSTO:ACE: -82.61

Ascelia Pharma AB ROE % Historical Data

The historical data trend for Ascelia Pharma AB's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ascelia Pharma AB ROE % Chart

Ascelia Pharma AB Annual Data
Trend Jun17 Jun18 Jun19 Dec20 Dec21 Dec22 Dec23
ROE %
Get a 7-Day Free Trial -19.15 -38.54 -46.30 -53.70 -85.65

Ascelia Pharma AB Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -89.23 -53.36 -97.33 -96.02 -111.97

Competitive Comparison of Ascelia Pharma AB's ROE %

For the Biotechnology subindustry, Ascelia Pharma AB's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ascelia Pharma AB's ROE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ascelia Pharma AB's ROE % distribution charts can be found below:

* The bar in red indicates where Ascelia Pharma AB's ROE % falls into.



Ascelia Pharma AB ROE % Calculation

Ascelia Pharma AB's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=-109.288/( (180.859+74.328)/ 2 )
=-109.288/127.5935
=-85.65 %

Ascelia Pharma AB's annualized ROE % for the quarter that ended in Sep. 2024 is calculated as

ROE %=Net Income (Q: Sep. 2024 )/( (Total Stockholders Equity (Q: Jun. 2024 )+Total Stockholders Equity (Q: Sep. 2024 ))/ count )
=-86.928/( (47.687+107.582)/ 2 )
=-86.928/77.6345
=-111.97 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Sep. 2024) net income data. ROE % is displayed in the 30-year financial page.


Ascelia Pharma AB  (OSTO:ACE) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Sep. 2024 )
=Net Income/Total Stockholders Equity
=-86.928/77.6345
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-86.928 / 0)*(0 / 128.183)*(128.183 / 77.6345)
=Net Margin %*Asset Turnover*Equity Multiplier
=N/A %*0*1.6511
=ROA %*Equity Multiplier
=N/A %*1.6511
=-111.97 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Sep. 2024 )
=Net Income/Total Stockholders Equity
=-86.928/77.6345
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-86.928 / -87.032) * (-87.032 / -71.16) * (-71.16 / 0) * (0 / 128.183) * (128.183 / 77.6345)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 0.9988 * 1.223 * N/A % * 0 * 1.6511
=-111.97 %

Note: The net income data used here is four times the quarterly (Sep. 2024) net income data. The Revenue data used here is four times the quarterly (Sep. 2024) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Ascelia Pharma AB ROE % Related Terms

Thank you for viewing the detailed overview of Ascelia Pharma AB's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Ascelia Pharma AB Business Description

Traded in Other Exchanges
N/A
Address
Hyllie Boulevard 34, Malmo, SWE, SE-215 32
Ascelia Pharma AB is an oncology-dedicated drug development company located in Malmo Sweden focused on orphan oncology It develops and commercializes novel drugs that address unmet medical needs and have a clear development and market pathway The company has two drug candidates Orviglance and Oncoral in clinical development.

Ascelia Pharma AB Headlines

No Headlines